SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR - News) today announced the publication of its Phase 1 clinical trials of OPT-80 in the April 2008 edition of Antimicrobial Agents and Chemotherapy published by the American Society for Microbiology. The article is entitled, “Safety, Tolerance and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers Following Single and Multiple Doses” (AAC April 2008; v. 52: 1391-1395). The results from these studies support the development of OPT-80 as an oral therapy for Clostridium difficile infection, or CDI. OPT-80 is currently being tested in Phase 3 clinical trials for CDI, also known as Clostridium difficile-associated diarrhea.
